William Reardon - Tekla Life Insider

Tekla Life Sciences Investors -- USA Fund  

USD 21.71  0.07  0.32%

Independent Trustee

Mr. William S. Reardon CPA is an Independent Trustee of HQ Life Sciences Investors. Mr. Reardon personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP, with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. Until 2002, Mr. Reardon was a business assurance partner in PwC Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firm public clients in SECregistered equity, convertible and RD limited partnership offerings and many initial public offerings. He serves on the Valuation and Audit Committees of each Fund. From 19982000 he served on the Board of the Emerging Companies Section of the Biotechnology Industry Organization and from 2000 to 2002 he served on the Board of Directors of the Massachusetts Biotechnology Council . During his professional career, he was a frequent speaker at BIO conferences and MBC Industry meetings on issues affecting biotechnology companies. He currently also serves as a board member and audit committee chair of two developmentstage public companies, Synta Pharmaceuticals and Idera Pharmaceuticals
Age: 68  Executive Since 2010  CPA    
Reardon is member of the American Institute of CPAs and the Massachusetts Society of CPAs, with an MBA from Harvard Business School and a BA in East Asian History from Harvard College.

William Reardon Latest Insider Activity

Management Performance (%)

Fund Summary

The fund is listed under null category and is part of null family.

Did you try this?

Run Pattern Recognition Now
   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
Hide  View All  Next  Launch Pattern Recognition
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Tekla Life Sciences Investors to your portfolio

Top Management

Tekla Life Sciences Leadership Team
William Reardon, Executive, CPA
Michael Bonney, Executive
Oleg Pohotsky, Executive, MBA
Lucinda Stebbins, Executive, CPA
Daniel Omstead, President
Uwe Reinhardt, Executive, Ph.D
Rakesh Jain, Executive

Fund Performance

Tekla Life Performance Indicators